首页> 外文期刊>Current Biomarker Findings >Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis
【24h】

Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis

机译:特发性肺纤维化生物标志物:临床实用性和了解疾病发病机理的一种方法

获取原文
       

摘要

Abstract: Idiopathic pulmonary fibrosis (IPF) is a typically fatal disease that remains incompletely understood despite intense study and the arrival of drugs that may alter the natural history of the disease. Rendering an accurate diagnosis and predicting prognosis remain challenging problems to clinicians. One potential solution to these clinical problems is the identification of IPF biomarkers, easily measured factors that can be employed to predict clinical behavior. Candidate biomarkers have been identified by research in the laboratory on potential culprit cells or genes that may contribute to the pathogenesis of IPF. In this review, we present the current data on a number of well-studied IPF biomarker candidates and their potential role in the pathogenesis of disease. We also establish a framework for evaluating utility of incorporating these IPF biomarkers into clinical practice.
机译:摘要:特发性肺纤维化(IPF)是一种典型的致命疾病,尽管进行了深入的研究并且药物的到来可能改变疾病的自然病程,但仍未完全了解。提出准确的诊断和预测预后仍然是临床医生面临的难题。这些临床问题的一种潜在解决方案是IPF生物标记物的鉴定,IPF生物标记物是易于测量的因子,可用于预测临床行为。候选生物标志物已通过实验室研究确定了可能导致IPF发病的潜在罪魁祸首细胞或基因。在这篇综述中,我们介绍了许多经过充分研究的IPF生物标志物候选物及其在疾病发病机理中的潜在作用的最新数据。我们还建立了评估将这些IPF生物标志物纳入临床实践的效用的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号